Eterna Therapeutics Inc. - Common StockShare · US1140822099 · ERNA (XNAS) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Eterna Therapeutics Inc. - Common Stock
No Price
01.05.2026 20:48
Current Prices from Eterna Therapeutics Inc. - Common Stock
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
NASDAQ
ERNA
USD
01.05.2026 20:48
0,15 USD
0,005 USD
+3,66 %
IEX
ERNA
USD
01.05.2026 19:56
0,15 USD
0,005 USD
+3,25 %
Share Float & Liquidity
Free Float31,77 %
Shares Float2,49 M
Shares Outstanding7,85 M
Company Profile for Eterna Therapeutics Inc. - Common Stock Share
Ernexa Therapeutics Inc., a preclinical-stage company, develops induces derived mesenchymal stem cells (iMSC) therapies for the treatment of solid tumors and autoimmune disease. The company's lead product is ERNA-101, an allogenic pro-inflammatory cytokine (IL-7/IL-15) secreting iMSC for the treatment of ovarian cancer; and ERNA-102, an anti-inflammatory cytokine (IL-10) secreting iMSC for the treatment of rheumatoid arthritis. It has a license agreement with Factor Bioscience Limited. The company was formerly known as Eterna Therapeutics Inc. and changed its name to Ernexa Therapeutics in March 2025. Ernexa Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
